Metabotropic glutamate receptors for parkinson's disease therapy

Parkinson's Disease

Volumn , Issue , 2013, Pages

  Gasparini, Fabrizio ^a   Di Paolo, Thérèse ^b,c   Gomez Mancilla, Baltazar ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 2 (3,5 DICHLOROPHENYLCARBAMOYL)CYCLOHEXANECARBOXYLIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ADX 48621; ADX 88178; AMANTADINE; AMN 082; AMPA RECEPTOR; ANTIPARKINSON AGENT; DIPRAGLURANT; GYKI 53405; IFENPRODIL; IONOTROPIC RECEPTOR; IONOTROPIC RECEPTOR ANTAGONIST; KAINIC ACID RECEPTOR; LEVODOPA; MAVOGLURANT; METABOTROPIC RECEPTOR; MRZ 8676; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; PERAMPANEL; REMACEMIDE; TALAMPANEL; TEZAMPANEL; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGONIST; BASAL GANGLION; CELL DEGENERATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ANTAGONISM; DYSKINESIA; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; MENTAL DISEASE; MOTOR CONTROL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 84880293957     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2013/196028     Document Type: Review

References (132)

1. Mercuri N. B., Bernardi G., The "magic" of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends in Pharmacological Sciences 2005 26 7 341 344 2-s2.0-20544476874 10.1016/j.tips.2005.05.002 (Pubitemid 40848494)
2. Fabbrini G., Brotchie J. M., Grandas F., Nomoto M., Goetz C. G., Levodopa-induced dyskinesias. Movement Disorders 2007 22 10 1379 1389 2-s2.0-34548030225 10.1002/mds.21475 (Pubitemid 47280623)
3. Ahlskog J. E., Muenter M. D., Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement Disorders 2001 16 3 448 458 2-s2.0-0035353725 10.1002/mds.1090 (Pubitemid 36041148)
4. Cristina S., Zangaglia R., Mancini F., Martignoni E., Nappi G., Pacchetti C., High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clinical Neuropharmacology 2003 26 3 146 150 2-s2.0-0037713995 10.1097/00002826-200305000-00008 (Pubitemid 36676293)
5. Facca A., Sanchez-Ramos J., High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Movement Disorders 1996 11 3 327 329 2-s2.0-0029936417 10.1002/mds.870110319 (Pubitemid 26138834)
6. Müngersdorf M., Sommer U., Sommer M., Reichmann H., High-dose therapy with ropinirole in patients with Parkinson's disease. Journal of Neural Transmission 2001 108 11 1309 1317 2-s2.0-0035212184 10.1007/s007020100007 (Pubitemid 33141305)
7. 2a-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders. European Neurology 2012 67 1 4 11 2-s2.0-82355172005 10.1159/000331768
8. Brotchie J., Antidyskinetic actions of amantadine in Parkinson's disease: are benefits maintained in the long term? Expert Review of Neurotherapeutics 2010 10 6 871 873 2-s2.0-77953205380 10.1586/ern.10.70
9. Tambasco N., Simoni S., Marsili E., Sacchini E., Murasecco D., Cardaioli G., Rossi A., Calabresi P., Clinical aspects and management of levodopa-induced dyskinesia. Parkinson's Disease 2012 2012 12 745947 10.1155/2012/745947
10. Chase T. N., Oh J. D., Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends in Neurosciences 2000 23 10 S86 S91 2-s2.0-0033677879
11. Calon F., Rajput A. H., Hornykiewicz O., Bédard P. J., Di Paolo T., Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiology of Disease 2003 14 3 404 416 2-s2.0-0346218258 10.1016/j.nbd.2003.07.003 (Pubitemid 37543519)
12. Johnson K. A., Conn P. J., Niswender C. M., Glutamate receptors as therapeutic targets for Parkinson's disease. CNS and Neurological Disorders 2009 8 6 475 491 2-s2.0-75849152052 10.2174/187152709789824606
13. Jenner P., Molecular mechanisms of L-DOPA-induced dyskinesia. Nature Reviews Neuroscience 2008 9 9 665 677 2-s2.0-50049087567 10.1038/nrn2471
14. Brotchie J., Fitzer-Attas C., Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 2009 72 7 S32 S38 2-s2.0-61949208134 10.1212/WNL.0b013e318198e0e9
15. 1 dopamine receptor signaling in levodopa-induced dyskinesia. Annals of Neurology 2005 57 1 17 26 2-s2.0-19944427055 10.1002/ana.20296 (Pubitemid 40053311)
16. Iravani M. M., Mccreary A. C., Jenner P., Striatal plasticity in Parkinson's disease and L-DOPA induced dyskinesia. Parkinsonism and Related Disorders 2012 18 1, supplement S123 S125 2-s2.0-84858633135
17. Iravani M. M., Jenner P., Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. Journal of Neural Transmission 2011 118 12 1661 1690 2-s2.0-84855193194 10.1007/s00702-011-0698-2
18. Berthet A., Bezard E., Dopamine receptors and l-dopa-induced dyskinesia. Parkinsonism and Related Disorders 2010 15 4, supplement S8 S12 2-s2.0-72649085036 10.1016/S1353-8020(09)70827-2
19. Blandini F., Porter R. H. P., Greenamyre J. T., Glutamate and Parkinson's disease. Molecular Neurobiology 1996 12 1 73 94 2-s2.0-0030080245 (Pubitemid 126718053)
20. Cenci M. A., Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia. Trends in Neurosciences 2007 30 5 236 243 2-s2.0-34047114733 10.1016/j.tins.2007.03.005 (Pubitemid 46654236)
21. Esposito E., Di Matteo V., Di Giovanni G., Death in the substantia nigra: a motor tragedy. Expert Review of Neurotherapeutics 2007 7 6 677 697 2-s2.0-34250365299 10.1586/14737175.7.6.677 (Pubitemid 46911617)
22. Cenci M. A., Ohlin K. E., Rylander D., Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. Parkinsonism and Related Disorders 2009 15 supplement 3 S59 S63 2-s2.0-71849091969 10.1016/S1353-8020(09)70782-5
23. Rajput A. H., Fenton M. E., Birdi S., Macaulay R., Is levodopa toxic to human substantia nigra? Movement Disorders 1997 12 5 634 638 2-s2.0-0030984046 10.1002/mds.870120503 (Pubitemid 27406256)
24. Boyce S., Rupniak N. M. J., Steventon M. J., Iversen S. D., Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clinical Neuropharmacology 1990 13 5 448 458 2-s2.0-0025140869 (Pubitemid 20285578)
25. Nakanishi S., Molecular diversity of glutamate receptors and implications for brain function. Science 1992 258 5082 597 603 2-s2.0-0026437728
26. Niswender C. M., Conn P. J., Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annual Review of Pharmacology and Toxicology 2010 50 295 322 2-s2.0-77949516412 10.1146/annurev.pharmtox.011008. 145533
27. Hovelsø N., Sotty F., Montezinho L. P., Pinheiro P. S., Herrik K. F., Mørk A., Therapeutic potential of metabotropic glutamate receptor modulators. Current Neuropharmacology 2012 10 1 12 48 2-s2.0-84857705629 10.2174/157015912799362805
28. Traynelis S. F., Wollmuth L. P., McBain C. J., Menniti F. S., Vance K. M., Ogden K. K., Hansen K. B., Yuan H., Myers S. J., Dingledine R., Glutamate receptor ion channels: structure, regulation, and function. Pharmacological Reviews 2010 62 3 405 496 2-s2.0-77952363301 10.1124/pr.109.002451
29. Tayarani-Binazir K., Jackson M. J., Rose S., McCreary A. C., Jenner P., The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Experimental Neurology 2010 226 2 320 327 2-s2.0-77958602475 10.1016/j.expneurol.2010.09.007
30. Zadow B., Schmidt W. J., The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic- induced catalepsy. Naunyn-Schmiedeberg's Archives of Pharmacology 1994 349 1 61 65 2-s2.0-0027955445 (Pubitemid 24045022)
31. Loschmann P.-A., Lange K. W., Kunow M., Rettig K.-J., Jahnig P., Honore T., Turski L., Wachtel H., Jenner P., Marsden C. D., Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. Journal of Neural Transmission 1991 3 3 203 213 2-s2.0-0025992357 10.1007/BF02259538
32. Loschmann P. A., Kunow M., Wachtel H., Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease. Journal of Neural Transmission, Supplement 1992 38 55 64 2-s2.0-0027008315 (Pubitemid 23026846)
33. Maj J., Rogoz Z., Skuza G., Kolodziejczyk K., Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist. Polish Journal of Pharmacology 1995 47 6 501 507 2-s2.0-0029585891 (Pubitemid 26037100)
34. Wachtel H., Kunow M., Loschmann P.-A., NBQX (6-nitro-sulfamoyl-benzo- quinoxaline-dione) and CPP (3-carboxy- piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neuroscience Letters 1992 142 2 179 182 2-s2.0-0026668693 10.1016/0304-3940(92) 90368-H
35. Klockgether T., Turski L., Honore T., Zhang Z., Gash D. M., Kurlan R., Greenamyre J. T., The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Annals of Neurology 1991 30 5 717 723 2-s2.0-0026074931
36. Marin C., Jimenez A., Bonastre M., Chase T. N., Tolosa E., Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Synapse 2000 36 4 267 274 (Pubitemid 30257311)
37. Juranyi Z., Sziray N., Marko B., Levay G., Harsing L. G. Jr., AMPA receptor blockade potentiates the stimulatory effect of L-DOPA on dopamine release in dopamine-deficient corticostriatal slice preparation. Critical Reviews in Neurobiology 2004 16 1-2 129 139 2-s2.0-9744252290 10.1615/CritRevNeurobiol.v16.i12.140 (Pubitemid 39586911)
38. Megyeri K., Marko B., Sziray N., Gacsalyi I., Juranyi Z., Levay G., Harsing L. G. Jr., Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism. Brain Research Bulletin 2007 71 5 501 507 2-s2.0-33846447144 10.1016/j.brainresbull. 2006.11.003 (Pubitemid 46149199)
39. Brotchie J. M., Nondopaminergic mechanisms in levodopa-induced dyskinesia. Movement Disorders 2005 20 8 919 931 2-s2.0-26444532429 10.1002/mds.20612 (Pubitemid 41419505)
40. Marin C., Jimnez A., Bonastre M., Vila M., Agid Y., Hirsch E. C., Tolosa E., LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse 2001 42 1 40 47 2-s2.0-0034860914 10.1002/syn.1097 (Pubitemid 32786422)
41. Konitsiotis S., Blanchet P. J., Verhagen L., Lamers E., Chase T. N., AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000 54 8 1589 1595 2-s2.0-0034090891 (Pubitemid 30226801)
42. Hashizume Y., Ohgoh M., Ueno M., Hanada T., Nishizawa Y., Effect of perampanel, a selective AMPA receptor antagonist, on L-DOPA-induced rotational behavior in L-DOPA primed 6-OHDA hemiparkinsonian rats. Proceedings of the Annual Meeting of the American Academy of Neurology 2008 P06.102
43. Mizuta E., Ueno M., Hanada T., Kuno S., Effects of perampanel, a selective AMPA receptor antagonist, on L-DOPA induced dyskinesia in MPTP-treated cynomolgus monkeys. Proceedings of the Annual Meeting of the American Academy of Neurology 2008 P06.101
44. Eggert K., Squillacote D., Barone P., Dodel R., Katzenschlager R., Emre M., Lees A. J., Rascol O., Poewe W., Tolosa E., Trenkwalder C., Onofrj M., Stocchi F., Nappi G., Kostic V., Potic J., Ruzicka E., Oertel W., Safety and efficacy of perampanel in advanced parkinson's disease: a randomized, placebo-controlled study. Movement Disorders 2010 25 7 896 905 2-s2.0-77951958360 10.1002/mds.22974
45. Lees A., Fahn S., Eggert K. M., Jankovic J., Lang A., Micheli F., Maral Mouradian M., Oertel W. H., Olanow C. W., Poewe W., Rascol O., Tolosa E., Squillacote D., Kumar D., Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Movement Disorders 2012 27 2 284 288 2-s2.0-84856952320 10.1002/mds.23983
46. Rascol O., Barone P., Behari M., Emre M., Giladi N., Olanow C. W., Ruzicka E., Bibbiani F., Squillacote D., Patten A., Tolosa E., Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clinical Neuropharmacology 2012 35 1 15 20 2-s2.0-84855825060 10.1097/WNF.0b013e318241520b
47. Picconi B., Piccoli G., Calabresi P., Synaptic dysfunction in Parkinson's disease. Advances in Experimental Medicine and Biology 2012 970 553 572 2-s2.0-84858121110 10.1007/978-3-7091-0932-8-24
48. Sonsalla P. K., Albers D. S., Zeevalk G. D., Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids 1998 14 1-3 69 74 2-s2.0-0031985359 10.1007/BF01345245 (Pubitemid 28051154)
49. Chase T. N., Oh J. D., Striatal mechanisms and pathogenesis of Parkinsonian signs and motor complications. Annals of Neurology 2000 47 4 S122 S130 2-s2.0-0034105156 (Pubitemid 30192017)
50. Nash J. E., Fox S. H., Henry B., Hill M. P., Peggs D., McGuire S., Maneuf Y., Hille C., Brotchie J. M., Crossman A. R., Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology 2000 165 1 136 142 2-s2.0-0033834442 10.1006/exnr.2000. 7444
51. Gomez-Mancilla B., Bedard P. J., Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP- treated monkeys. Clinical Neuropharmacology 1993 16 5 418 427 2-s2.0-0027384928 (Pubitemid 23292096)
52. Blanchet P. J., Konitsiotis S., Whittemore E. R., Zhou Z. L., Woodward R. M., Chase T. N., Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys. Journal of Pharmacology and Experimental Therapeutics 1999 290 3 1034 1040 2-s2.0-0032797570 (Pubitemid 29400241)
53. Tahar A. H., Grégoire L., Darré A., Bélanger N., Meltzer L., Bédard P. J., Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiology of Disease 2004 15 2 171 176 2-s2.0-1542360582 10.1016/j.nbd.2003.10.007 (Pubitemid 38296747)
54. Papa S. M., Chase T. N., Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Annals of Neurology 1996 39 5 574 578 2-s2.0-0029665122
55. Morissette M., Dridi M., Calon F., Tahar A. H., Meltzer L. T., Bédard P. J., Di Paolo T., Prevention of levodopa-induced dyskinesias by a selective NRA1/2B N-methyl-D-aspartate receptor antagonist in Parkinsonian monkeys: implication of preproenkephalin. Movement Disorders 2006 21 1 9 17 2-s2.0-33244473485 10.1002/mds.20654 (Pubitemid 43273744)
56. Dall'Olio R., Rimondini R., Gandolfi O., The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function. Psychopharmacology 1995 118 3 310 315 2-s2.0-0028915585
57. Klockgether T., Turski L., NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Annals of Neurology 1990 28 4 539 546 2-s2.0-0025146826 (Pubitemid 20359161)
58. Bibbiani F., Oh J. D., Kielaite A., Collins M. A., Smith C., Chase T. N., Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Experimental Neurology 2005 196 2 422 429 2-s2.0-27744571228 10.1016/j.expneurol.2005.08.017 (Pubitemid 41607831)
59. Riahi G., Morissette M., Parent M., Di Paolo T., Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesias. European Journal of Neuroscience 2011 33 10 1823 1831 2-s2.0-79955948512 10.1111/j.1460-9568.2011. 07675.x
60. Paquette M. A., Martinez A. A., Macheda T., Meshul C. K., Johnson S. W., Berger S. P., Giuffrida A., Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. European Journal of Neuroscience 2012 36 9 3224 3234
61. 2a receptors. Synapse 2006 60 3 239 250 2-s2.0-33745810560 10.1002/syn.20295 (Pubitemid 44036718)
62. Mitchell I. J., Carroll C. B., Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neuroscience and Biobehavioral Reviews 1997 21 4 469 475 2-s2.0-0030990697 10.1016/S0149-7634(96)00036-X (Pubitemid 27255851)
63. Steece-Collier K., Chambers L. K., Jaw-Tsai S. S., Menniti F. S., Greenamyre J. T., Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit- containing N-methyl-D-aspartate receptors. Experimental Neurology 2000 163 1 239 243 2-s2.0-0034067617 10.1006/exnr.2000.7374 (Pubitemid 30314379)
64. Paoletti P., Neyton J., NMDA receptor subunits: function and pharmacology. Current Opinion in Pharmacology 2007 7 1 39 47 2-s2.0-33846920665 10.1016/j.coph.2006.08.011 (Pubitemid 46238036)
65. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., Larsen J. P., Lees A., Oertel W., Poewe W., Rascol O., Sampaio C., Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. European Journal of Neurology 2006 13 11 1186 1202 2-s2.0-33750077251 10.1111/j.1468-1331.2006.01548.x (Pubitemid 44581465)
66. Pahwa R., Factor S. A., Lyons K. E., Ondo W. G., Gronseth G., Bronte-Stewart H., Hallett M., Miyasaki J., Stevens J., Weiner W. J., Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 66 7 983 995 2-s2.0-33646076457 10.1212/01.wnl.0000215250.82576.87 (Pubitemid 44044780)
67. Blanchet P. J., Konitsiotis S., Chase T. N., Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Movement Disorders 1998 13 5 798 802 2-s2.0-0031689728 10.1002/mds.870130507 (Pubitemid 28429978)
68. Dekundy A., Lundblad M., Danysz W., Cenci M. A., Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behavioural Brain Research 2007 179 1 76 89 2-s2.0-33947302427 10.1016/j.bbr.2007.01.013 (Pubitemid 46441485)
69. Del Dotto P., Pavese N., Gambaccini G., Bernardini S., Metman L. V., Chase T. N., Bonuccelli U., Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Movement Disorders 2001 16 3 515 520 2-s2.0-0035353741 10.1002/mds.1112 (Pubitemid 36041158)
70. Da Silva-Júnior F. P., Braga-Neto P., Sueli Monte F., Meireles Sales De Bruin V., Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism and Related Disorders 2005 11 7 449 452 2-s2.0-27344444293 10.1016/j.parkreldis. 2005.05.008 (Pubitemid 41526996)
71. Sawada H., Oeda T., Kuno S., Nomoto M., Yamamoto K., Yamamoto M., Hisanaga K., Kawamura T., Amantadine for dyskinesias in parkinson's disease: a randomized controlled trial. PLoS One 2010 5 12 2-s2.0-79251522860 10.1371/journal.pone.0015298 e15298
72. Metman L. V., Del Dotto P., Van Den Munckhof P., Fang J., Mouradian M. M., Chase T., Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998 50 5 1323 1326 2-s2.0-0006647256 (Pubitemid 28240346)
73. Elahi B., Phielipp N., Chen R., N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. The Canadian Journal of Neurological Sciences 2012 39 4 465 472
74. Goetz C. G., Stebbins G. T., Chung K. A., Hauser R. A., Miyasaki J. M., Nicholas A. P., Poewe W., Seppi K., Rascol O., Stacy M. A., Nutt J. G., Tanner C. M., Urkowitz A., Jaglin J. A., Ge S., Which dyskinesia scale best detects treatment response? A double-blind placebo controlled multicenter trial using multiple dyskinesia outcomes. Proceedings of the 16th International Congress of Parkinson's Disease and Movement Disorders 2012 abstract LBA 11
75. Wolf E., Seppi K., Katzenschlager R., Hochschorner G., Ransmayr G., Schwingenschuh P., Ott E., Kloiber I., Haubenberger D., Auff E., Poewe W., Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Movement Disorders 2010 25 10 1357 1363 2-s2.0-77953184604 10.1002/mds.23034
76. Ory-Magne F., Thalamas C., Galitsky M., Salis A., Sommet A., Pourcel L., Azulay J. P., Long-term effects of amantadine in Parkinsonian (AMANDYSK). Movement Disorders 2012 27 supplement 14, article 12
77. Schwid S. R., A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Neurology 2000 54 8 1583 1588 2-s2.0-0342424715 (Pubitemid 30226800)
78. De Marcaida J. A., Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Archives of Neurology 2001 58 10 1660 1668 2-s2.0-0034793204 (Pubitemid 32963232)
79. Clarke C. E., Cooper J. A., Holdich T. A. H., A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations. Clinical Neuropharmacology 2001 24 3 133 138 2-s2.0-0034977386 10.1097/00002826- 200105000-00003 (Pubitemid 32549987)
80. Montastruc J. L., Rascol O., Senard J. M., Rascol A., A pilot study of N-Methyl-D-Aspartate (NMDA) antagonist in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1992 55 7 630 631 2-s2.0-0026725656
81. Nutt J. G., Gunzler S. A., Kirchhoff T., Hogarth P., Weaver J. L., Krams M., Jamerson B., Menniti F. S., Landen J. W., Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism. Movement Disorders 2008 23 13 1860 1866 2-s2.0-57049160908 10.1002/mds.22169
82. Schwid S. R., A randomized, controlled trial of remacemide for motor fluctuations in parkinson's disease: parkinson study group. Neurology 2001 56 4 455 462 2-s2.0-0035957065 (Pubitemid 32172868)
83. Rylander D., Recchia A., Mela F., Dekundy A., Danysz W., Cenci Nilsson M. A., Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. Journal of Pharmacology and Experimental Therapeutics 2009 330 1 227 235 2-s2.0-67649847847 10.1124/jpet.108.150425
84. Shigemoto R., Mizuno N., Ottersen O. P., Storm-Mathisen J., Metabotropic glutamate receptors-immunocytochemical and in situ hybridization analysis. Handbook of Chemical Neuroanatomy 2000 18 Elsevier 63 98
85. Conn P. J., Battaglia G., Marino M. J., Nicoletti F., Metabotropic glutamate receptors in the basal ganglia motor circuit. Nature Reviews Neuroscience 2005 6 10 787 798 2-s2.0-27944470972 10.1038/nrn1763 (Pubitemid 41679241)
86. Romano C., Sesma M. A., McDonald C. T., O'Malley K., Van den Pol A. N., Olney J. W., Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. Journal of Comparative Neurology 1995 355 3 455 469 2-s2.0-0029002053
87. 5 receptor antagonist 2-methyl-6-(phenylethynyl)- pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. European Journal of Pharmacology 2000 406 3 403 410 2-s2.0-0034693328 10.1016/S0014-2999(00)00697-X
88. Breysse N., Baunez C., Spooren W., Gasparini F., Amalric M., Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of Parkinsonism. Journal of Neuroscience 2002 22 13 5669 5678 2-s2.0-0036662945 (Pubitemid 35386488)
89. Levandis G., Bazzini E., Armentero M.-T., Nappi G., Blandini F., Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiology of Disease 2008 29 1 161 168 2-s2.0-36549085132 10.1016/j.nbd.2007.08.011 (Pubitemid 350180490)
90. Ossowska K., Konieczny J., Wolfarth S., Pilc A., MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology 2005 49 4 447 455 2-s2.0-23844436731 10.1016/j.neuropharm.2005.04.002 (Pubitemid 41169969)
91. Samadi P., Grégoire L., Morissette M., Calon F., Hadj Tahar A., Dridi M., Belanger N., Meltzer L. T., Bédard P. J., Di Paolo T., mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiology of Aging 2008 29 7 1040 1051 2-s2.0-43849110886 10.1016/j.neurobiolaging.2007. 02.005 (Pubitemid 351697993)
92. Ouattara B., Grégoire L., Morissette M., Gasparini F., Vranesic I., Bilbe G., Johns D. R., Rajput A., Hornykiewicz O., Rajput A. H., Gomez-Mancilla B., Di Paolo T., Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiology of Aging 2011 32 7 1286 1295 2-s2.0-79958770950 10.1016/j.neurobiolaging.2009.07.014
93. Konradi C., Westin J. E., Carta M., Eaton M. E., Kuter K., Dekundy A., Lundblad M., Cenci M. A., Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiology of Disease 2004 17 2 219 236 2-s2.0-5144228175 10.1016/j.nbd.2004.07.005 (Pubitemid 39345778)
94. Awad H., Hubert G. W., Smith Y., Levey A. I., Conn P. J., Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. Journal of Neuroscience 2000 20 21 7871 7879 2-s2.0-0034332480
95. Pisani A., Calabresi P., Centonze D., Bernardi G., Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. British Journal of Pharmacology 1997 120 6 1007 1014 2-s2.0-0030898586 10.1038/sj.bjp.0700999 (Pubitemid 27122637)
96. 2a receptors on metabotropic glutamate receptor 5 (mGluR5)-mediated effects in the striatum. Journal of Neurochemistry 2004 90 5 1276 1279 2-s2.0-4444382866 10.1111/j.1471-4159.2004. 02607.x (Pubitemid 39167361)
97. 2a receptor signaling. Proceedings of the National Academy of Sciences of the United States of America 2003 100 3 1322 1327 2-s2.0-0037417810 10.1073/pnas.0237126100 (Pubitemid 36184000)
98. 2a receptors. Neuropsychopharmacology 2001 25 4 505 513 2-s2.0-0034856088 10.1016/S0893-133X(01)00256-1 (Pubitemid 32830955)
99. 2 receptors. Neuroscience Letters 2002 324 2 154 158 2-s2.0-0037123728 10.1016/S0304-3940(02)00179-9 (Pubitemid 34457827)
100. 5 Receptor antagonist SIB-1830 reduces L-Dopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Proceedings of the Neuroscience Meeting Planner 2001 San Diego, Calif, USA Society for Neuroscience
101. Varney M. A., Cosford N. D. P., Jachec C., Rao S. P., Sacaan A., Lin F.-F., Bleicher L., Santori E. M., Flor P. J., Allgeier H., Gasparini F., Kuhn R., Hess S. D., Veliçelebi G., Johnson E. C., SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. Journal of Pharmacology and Experimental Therapeutics 1999 290 1 170 181 2-s2.0-0033004276 (Pubitemid 29302317)
102. Mathiesen J. M., Svendsen N., Bräuner-Osborne H., Thomsen C., Ramirez M. T., Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. British Journal of Pharmacology 2003 138 6 1026 1030 2-s2.0-0037363728 10.1038/sj.bjp.0705159 (Pubitemid 36459824)
103. Dekundy A., Pietraszek M., Schaefer D., Cenci M. A., Danysz W., Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Research Bulletin 2006 69 3 318 326 2-s2.0-33645050113 10.1016/j.brainresbull.2005.12.009
104. Mela F., Marti M., Dekundy A., Danysz W., Morari M., Cenci M. A., Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. Journal of Neurochemistry 2007 101 2 483 497 2-s2.0-34047186385 10.1111/j.1471-4159.2007.04456.x (Pubitemid 46525288)
105. Morin N., Grégoire L., Gomez-Mancilla B., Gasparini F., Di Paolo T., Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010 58 7 981 986 2-s2.0-77950958966 10.1016/j.neuropharm.2009.12.024
106. 5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology 2012 355 364 10.1016/j.neuropharm.2012.07.036
107. Grégoire L., Morin N., Ouattara B., Gasparini F., Bilbe G., Johns D., Vranesic I., Sahasranaman S., Gomez-Mancilla B., Di Paolo T., The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys. Parkinsonism and Related Disorders 2011 17 4 270 276 2-s2.0-79954995144 10.1016/j.parkreldis.2011.01.008
108. Berg D., Godau J., Trenkwalder C., Eggert K., Csoti I., Storch A., Huber H., Morelli-Canelo M., Stamelou M., Ries V., Wolz M., Schneider C., Di Paolo T., Gasparini F., Hariry S., Vandemeulebroecke M., Abi-Saab W., Cooke K., Johns D., Gomez-Mancilla B., AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Movement Disorders 2011 26 7 1243 1250 2-s2.0-79959372108 10.1002/mds.23616
109. Stocchi F., Destee A., Hattori N., Hauser R. A., Lang A. E., Poewe W., Rascol O., Stacy M., Tolosa E., Trenkwalder C., Gao H., Nagel J., Gomez-Mancilla B., A 13-week, double-blind, placebo-controlled study of AFQ056, a metabotropic glutamate receptor 5 antagonist in Parkinson's disease patients with moderate-to-severe L-dopa-induced dyskinesias. 2011 Proceedings of the 15th International Congress of Parkinson's Disease and Movement Disorders 2011 Toronto, Canada
110. Tison F., Durif F., Corvol J. C., Eggert K., Trenkwalder C., Lew M., Isaacson S., Keywood C., Rascol O., Safety, tolerability and anti-dyskinetic efficacy of dipaglurant, a novel mGluR5 negative allosteric modulator (NAM), in Parkinson's disease patients with levodopa-induced dyskinesia (LID). 2012 Proceedings of the 16th International Congress of Parkinson's Disease and Movement Disorders June2012 Dublin, Ireland
111. Amalric M., Lopez S., Goudet C., Fisone G., Battaglia G., Nicoletti F., Pin J. P., Acher F. C., Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease. Neuropharmacology 2013 66 53 64 10.1016/j.neuropharm.2012.05.026
112. Lindsley C. W., Hopkins C. R., Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature. Expert Opinion on Therapeutic Patents 2012 22 5 461 481
113. Matsui T., Kita H., Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus. Neuroscience 2003 122 3 727 737 2-s2.0-0242401905 10.1016/j.neuroscience.2003.08.032 (Pubitemid 37410294)
114. Lopez S., Turle-Lorenzo N., Acher F., De Leonibus E., Mele A., Amalric M., Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. Journal of Neuroscience 2007 27 25 6701 6711 2-s2.0-34250830873 10.1523/JNEUROSCI.0299-07. 2007 (Pubitemid 46983444)
115. Beurrier C., Lopez S., Révy D., Selvam C., Goudet C., Lhérondel M., Gubellini P., Kerkerian-LeGoff L., Acher F., Pin J.-P., Amalric M., Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB Journal 2009 23 10 3619 3628 2-s2.0-70349695699 10.1096/fj.09-131789
116. Valenti O., Marino M. J., Wittmann M., Lis E., DiLella A. G., Kinney G. G., Conn P. J., Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. Journal of Neuroscience 2003 23 18 7218 7226 2-s2.0-0042626528 (Pubitemid 36975886)
117. Marino M. J., Williams D. L. Jr., O'Brien J. A., Valenti O., McDonald T. P., Clements M. K., Wang R., DiLella A. G., Hess J. F., Kinney G. G., Conn P. J., Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proceedings of the National Academy of Sciences of the United States of America 2003 100 23 13668 13673 2-s2.0-0345686620 10.1073/pnas.1835724100 (Pubitemid 37444797)
118. Battaglia G., Busceti C. L., Molinaro G., Biagioni F., Traficante A., Nicoletti F., Bruno V., Pharmacological activation of mGlu4 metabotropic
119. Niswender C. M., Johnson K. A., Weaver C. D., Jones C. K., Xiang Z., Luo Q., Rodriguez A. L., Marlo J. E., De Paulis T., Thompson A. D., Days E. L., Nalywajko T., Austin C. A., Williams M. B., Ayala J. E., Williams R., Lindsley C. W., Conn P. J., Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Molecular Pharmacology 2008 74 5 1345 1358 2-s2.0-54349110319 10.1124/mol.108.049551
120. Jones C. K., Bubser M., Thompson A. D., Dickerson J. W., Turle-Lorenzo N., Amalric M., Blobaum A. L., Bridges T. M., Morrison R. D., Jadhav S., Engers D. W., Italiano K., Bode J., Daniels J. S., Lindsley C. W., Hopkins C. R., Conn P. J., Niswender C. M., The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics 2012 340 2 404 421 2-s2.0-84856022448 10.1124/jpet.111.187443
121. Le Poul E., Boléa C., Girard F., Poli S., Charvin D., Campo B., Bortoli J., Bessif A., Luo B., Koser A. J., Hodge L. M., Smith K. M., DiLella A. G., Liverton N., Hess F., Browne S. E., Reynolds I. J., A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics 2012 343 1 167 177
122. Greco B., Lopez S., Van Der Putten H., Flor P. J., Amalric M., Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics 2010 332 3 1064 1071 2-s2.0-77249085779 10.1124/jpet.109.162115
123. Johnson K. A., Jones C. K., Tantawy M. N., Bubser M., Marvanova M., Ansari M. S., Baldwin R. M., Conn P. J., Niswender C. M., The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. Neuropharmacology 2012 66 187 195 2-s2.0-84860616995 10.1016/j.neuropharm.2012.03.029
124. Schoepp D. D., Wright R. A., Levine L. R., Gaydos B., Potter W. Z., LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003 6 3 189 197 2-s2.0-0141644133 10.1080/ 1025389031000146773 (Pubitemid 37210425)
125. Kinon B. J., Zhang L., Millen B. A., Osuntokun O. O., Williams J. E., Kollack-Walker S., Jackson K., Kryzhanovskaya L., Jarkova N., A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. Journal of Clinical Psychopharmacology 2011 31 3 349 355 2-s2.0-79955594301 10.1097/JCP. 0b013e318218dcd5
126. Bradley S. R., Marino M. J., Wittmann M., Rouse S. T., Awad H., Levey A. I., Conn P. J., Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata. Journal of Neuroscience 2000 20 9 3085 3094 2-s2.0-0034193374 (Pubitemid 30263125)
127. Dawson L., Chadha A., Megalou M., Duty S., The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. British Journal of Pharmacology 2000 129 3 541 546 2-s2.0-0033967160 (Pubitemid 30083876)
128. Samadi P., Grégoire L., Morissette M., Calon F., Tahar A. H., Bélanger N., Dridi M., Bédard P. J., Di Paolo T., Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias. Neuropharmacology 2008 54 2 258 268 2-s2.0-38149091686 10.1016/j.neuropharm.2007.08.009
129. Samadi P., Rajput A., Calon F., Grégoire L., Hornykiewicz O., Rajput A. H., Di Paolo T., Metabotropic glutamate receptor II in the brains of parkinsonian patients. Journal of Neuropathology and Experimental Neurology 2009 68 4 374 382 2-s2.0-65349101603 10.1097/NEN.0b013e31819cabe4
130. Murray T. K., Messenger M. J., Ward M. A., Woodhouse S., Osborne D. J., Duty S., O'Neill M. J., Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacology Biochemistry and Behavior 2002 73 2 455 466 2-s2.0-0035996544 10.1016/S0091-3057(02)00842-0 (Pubitemid 34765583)
131. 5 potentiators and antagonists. Biochemical Society Transactions 2004 32 5 881 887 2-s2.0-8744227147 10.1042/BST0320881 (Pubitemid 39524404)
132. Johnson P. L., Fitz S. D., Engleman E. A., Svensson K. A., Schkeryantz J. M., Shekhar A., Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats. Journal of Psychopharmacology 2012 27 2 152 161 10.1177/0269881112454230